Lakewood-Amedex Biotherapeutics Inc. (LABT)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-31
Fiscal PeriodQ1-FY2026
Total Assets196,343$481,598$
Total Current Assets50,626$305,389$
Cash and Cash Equivalents11,709$236,400$
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets145,717$176,209$
Goodwill
Other Intangible Assets
Physical Assets8,066$9,225$
Other Noncurrent Assets8,132$8,132$
Assets Held for Sale in Long Term
Total Liabilities3,037,991$2,446,135$
Total Current Liabilities3,027,696$2,405,100$
Accounts Payable547,829$381,041$
Short Term Debt
Short Term Capital Lease Obligations121,044$119,306$
Other Current Liabilities
Total Noncurrent Liabilities10,295$41,035$
Long Term Debt
Long Term Capital Lease Obligations10,295$41,035$
Other Noncurrent Liabilities
Total Equity(2,841,648$)(1,964,537$)(76,233$)
Equity to Minority
Equity to Common Shareholders(2,841,648$)(1,964,537$)(76,233$)
Additional Paid-In Capital51,579,029$51,532,849$
Retained Earnings(54,274,421$)(53,351,130$)
Treasury Stock150,000$150,000$
Capital Lease Obligations131,339$